Neuraltus Pharmaceuticals, Inc., is a privately-held pharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases, such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
Neuraltus announced findings from a confirmatory Phase 2 study of its investigational therapy, NP001, in amyotrophic lateral sclerosis (ALS) patients with elevated levels of systemic inflammation. The study, which enrolled 138 patients, did not meet its primary or secondary endpoints. The top-line data were presented during a podium presentation at the American Academy of Neurology’s 70th Annual Meeting in Los Angeles on April 26, 2017. For more information, please see the Company press release here.